Nektar Therapeutics: Premium Company Profile

Publication Date	December 2007
Publisher	Datamonitor
Product Type	Databook
Pages	60
ISBN Number	not applicable
Product Code	DAT09421

Price

£265.00
approximately: $521 | €337

PRINT £265 ($521 | €337)

Order above formats by FAX

Summary

Introduction

Nektar Therapeutics is a biopharmaceutical company, which creates differentiated, innovative products by applying its platform technologies to established or novel medicines. Nektar's two leading technology platforms are Pulmonary Technology and PEGylation Technology.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Nektar's technology platforms enable improved performance of a variety of new and existing molecules. Its Pulmonary Technology makes drugs inhaleable to deliver them to and through the lungs for both systemic and local lung applications.

PEGylation Technology is a chemical process designed to enhance the performance of most drug classes with the potential to improve solubility and stability, increase drug half-life, reduce immune responses to an active drug, and improve the efficacy or safety of a molecule in certain instances.

Nektar's development programs focus on products that fill unmet needs in diabetes, infectious disease, and oncology. Nektar's business strategy is to maximize the diabetes opportunity, develop own proprietary products, and maintain and create high value partnerships.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Overview
Catalyst
- Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Locations and Subsidiaries
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Business Segment Performance
- Geographic Segment Performance
- Products & Services
- Marketed Products
- Pipeline Products
- AC Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Discovery and Product Development
- Manufacturing
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask the analyst
- Datamonitor consulting
- Disclaimer
- Figure 1: Nektar Therapeutics - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: Nektar Therapeutics - Key Strategic Revenues, 2002-2006 ($ Mn)
- Figure 3: Nektar Therapeutics - Key Strategic Revenues, 2006-2010 ($ Mn)
- Table 1: Nektar Therapeutics - Key Facts
- Table 2: Nektar Therapeutics - Other Locations and Subsidiaries
- Table 3: Nektar Therapeutics - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 4: Nektar Therapeutics - Key Events Impacting Share Price Performance
- Table 5: Nektar Therapeutics - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 6: Nektar Therapeutics - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
- Table 7: Nektar Therapeutics - Balance Sheet, 2002-2006 ($ Mn)
- Table 8: Nektar Therapeutics - Cash Flow, 2002-2006 ($ Mn)
- Table 9: Nektar Therapeutics - Revenue Breakdown by Division, 2002-2006 ($ Mn)
- Table 10: Nektar Therapeutics - Geographic Breakdown, 2002-2006 ($ Mn)
- Table 11: Nektar Therapeutics - Marketed Products
- Table 12: Nektar Therapeutics - in-house Pipeline Products
- Table 13: Nektar Therapeutics - Collaboration Products
- Table 14: Nektar Therapeutics - Forecast Sales, 2006-2010 ($ Mn)
- Table 15: Nektar Therapeutics - Key Competitors
- Table 16: Nektar Therapeutics - Key Clients
- Table 17: Nektar Therapeutics - Key Shareholders
- Table 18: Nektar Therapeutics - SWOT Analysis Summary
- Table 19: Nektar Therapeutics - Value Chain Analysis
- Table 20: Nektar Therapeutics - Scorecard
- Table 21: Nektar Therapeutics - Key Employees
- Table 22: Nektar Therapeutics - Core Indicators